261 related articles for article (PubMed ID: 8289472)
1. Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study.
Laczika K; Mitterbauer G; Korninger L; Knöbl P; Schwarzinger I; Kapiotis S; Haas OA; Kyrle PA; Pont J; Oehler L
Leukemia; 1994 Jan; 8(1):1-5. PubMed ID: 8289472
[TBL] [Abstract][Full Text] [Related]
2. Molecular monitoring of minimal residual disease in acute promyelocytic leukemia by the polymerase chain reaction assay for the PML/RAR alpha (retinoic acid receptor-alpha) fusion transcript in patients treated with all-trans retinoic acid followed by chemotherapy.
Nemet D; Grahovac B; Labar B; Mrsić M; Radman I; Bogdanić V; Hitrec V; Zaher D; Aurer I; Sertić D
Haematologica; 1995; 80(3):238-40. PubMed ID: 7672716
[TBL] [Abstract][Full Text] [Related]
3. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
[TBL] [Abstract][Full Text] [Related]
4. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA.
Miller WH; Levine K; DeBlasio A; Frankel SR; Dmitrovsky E; Warrell RP
Blood; 1993 Sep; 82(6):1689-94. PubMed ID: 8400225
[TBL] [Abstract][Full Text] [Related]
5. Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia.
Koller E; Karlic H; Krieger O; Mistrik M; Michlmayr G; Gadner H; Lutz D; Heinz R; Pittermann E
Ann Hematol; 1995 Feb; 70(2):75-8. PubMed ID: 7880927
[TBL] [Abstract][Full Text] [Related]
6. Detection of minimal residual disease in a patient with acute promyelocytic leukemia by RT-PCR: necessity of chemotherapy following ATRA therapy.
Sun T; Takatsuki H; Yamashita S; Yufu Y; Umemura T; Nishimura J; Nawata H
Fukuoka Igaku Zasshi; 1994 Feb; 85(2):52-6. PubMed ID: 8144129
[TBL] [Abstract][Full Text] [Related]
7. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation.
Perego RA; Marenco P; Bianchi C; Cairoli R; Urbano M; Nosari AM; Muti G; Morra E; Del Monte U
Leukemia; 1996 Feb; 10(2):207-12. PubMed ID: 8637228
[TBL] [Abstract][Full Text] [Related]
8. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
Meloni G; Diverio D; Vignetti M; Avvisati G; Capria S; Petti MC; Mandelli F; Lo Coco F
Blood; 1997 Aug; 90(3):1321-5. PubMed ID: 9242568
[TBL] [Abstract][Full Text] [Related]
9. PML-RAR alpha fusion transcripts by RNA PCR in acute promyelocytic leukemia in remission and its correlation with clinical outcome.
Ikeda K; Sasaki K; Tasaka T; Nagai M; Kawanishi K; Takahara J; Irino S
Int J Hematol; 1994 Oct; 60(3):197-205. PubMed ID: 7858239
[TBL] [Abstract][Full Text] [Related]
10. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.
Slack JL; Arthur DC; Lawrence D; Mrózek K; Mayer RJ; Davey FR; Tantravahi R; Pettenati MJ; Bigner S; Carroll AJ; Rao KW; Schiffer CA; Bloomfield CD
J Clin Oncol; 1997 May; 15(5):1786-95. PubMed ID: 9164186
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.
Gau JP; Young JH; Lin TH; Yang YS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):175-81. PubMed ID: 10746412
[TBL] [Abstract][Full Text] [Related]
12. Acute promyelocytic leukemia: from clinic to molecular biology.
Chen SJ; Wang ZY; Chen Z
Stem Cells; 1995 Jan; 13(1):22-31. PubMed ID: 7719245
[TBL] [Abstract][Full Text] [Related]
13. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
[TBL] [Abstract][Full Text] [Related]
14. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.
Visani G; Buonamici S; Malagola M; Isidori A; Piccaluga PP; Martinelli G; Ottaviani E; Grafone T; Baccarani M; Tura S
Leukemia; 2001 Nov; 15(11):1696-700. PubMed ID: 11681409
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of semiquantitative reverse transcriptase-polymerase chain reaction assay of PML/retinoic acid receptor alpha mRNA and in vitro differentiation assay as prognostic prediction in acute promyelocytic leukemia treated with all-trans retinoic acid.
Iwakiri R; Inokuchi K; Dan K; Wakabayashi I
Nihon Ika Daigaku Zasshi; 1996 Aug; 63(4):259-67. PubMed ID: 8810554
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Thomas X; Dombret H; Cordonnier C; Pigneux A; Gardin C; Guerci A; Vekhoff A; Sadoun A; Stamatoullas A; Fegueux N; Maloisel F; Cahn JY; Reman O; Gratecos N; Berthou C; Huguet F; Kotoucek P; Travade P; Buzyn A; de Revel T; Vilque JP; Naccache P; Chomienne C; Degos L; Fenaux P
Leukemia; 2000 Jun; 14(6):1006-13. PubMed ID: 10865965
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse.
Grimwade D; Howe K; Langabeer S; Burnett A; Goldstone A; Solomon E
Leukemia; 1996 Jan; 10(1):61-6. PubMed ID: 8558940
[TBL] [Abstract][Full Text] [Related]
18. Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases.
Liso V; Specchia G; Pogliani EM; Palumbo G; Mininni D; Rossi V; Teruzzi E; Mestice A; Coppi MR; Biondi A
Cancer; 1998 Oct; 83(8):1522-8. PubMed ID: 9781945
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of all-trans retinoic acid as post-remission therapy in patients with acute promyelocytic leukemia.
Seiter K; Miller WH; Feldman EJ; Ahmed T; Arlin Z
Leukemia; 1995 Jan; 9(1):15-8. PubMed ID: 7845010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
